Trial | NCT01043367  Report issue

Title

Deprexil in Subjects With Signs and Symptoms of Depression
Efficacy of Deprexil Administration in Subjects With Signs and Symptoms of Depression.

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    200
The purpose of the study is to assess the efficacy of DEPREXIL administration in combination with relaxation psychotherapy in the treatment of patients with signs and symptoms of depression. The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks. The estimated number of persons to be recruited and randomized for the study is 200.
Study Started
Jan 31
2010
Primary Completion
Jan 31
2011
Study Completion
Jan 31
2011
Last Update
Mar 08
2011
Estimate

Dietary Supplement Deprexil

One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.

Dietary Supplement Placebo

One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.

A Experimental

Deprexil

B Placebo Comparator

Placebo

Criteria 

Inclusion Criteria:

Mild or moderate symptoms and signs of depression for more than 3 months and less than 3 years of duration.
Signed informed consent

Exclusion Criteria:

Severe symptoms and signs of depression or Suicide proneness.
Pregnancy or breastfeeding
Receiving other experimental drug
Use of anti-depressive medication within 15 days
No Results Posted